Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Delta Financial Advisors LLC

Delta Financial Advisors LLC trimmed its stake in Bristol-Myers Squibb (NYSE:BMY) by 38.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 17,988 shares of the biopharmaceutical company’s stock after selling 11,231 shares during the period. Delta Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $923,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in Bristol-Myers Squibb during the third quarter worth $25,000. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth about $26,000. Milestone Investment Advisors LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $27,000. Coppell Advisory Solutions LLC acquired a new position in Bristol-Myers Squibb in the 2nd quarter valued at about $28,000. Finally, Blue Bell Private Wealth Management LLC increased its stake in Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.30 during trading hours on Thursday, reaching $48.14. 3,745,537 shares of the company’s stock were exchanged, compared to its average volume of 15,683,751. The company’s 50 day moving average is $51.26 and its two-hundred day moving average is $51.59. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The company has a market cap of $97.57 billion, a P/E ratio of 12.46, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter last year, the firm posted $1.82 EPS. The business’s revenue was up .6% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.47 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.99%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.